Authors
Abstract
Background and Purpose: Type II diabetes is a chronic disease characterized by insulin resistance, impaired insulin secretion and increased hepatic glucose production. Metformin is a biguanide which reduces the production of hepatic glucose and is able to increase the sensitivity of peripheral tissue to insulin. This study was designed to investigate the effect of metformin on lipid profile and body weight.
Methods and Materials: In this clinical trial, 51 type II diabetic patients, admitted to Yazd Research Crnter of Diabetes, with FBS>150 mg/dl, Tg>200 mg/dl and BMI>25 kg/m2 and no previous history of metformin use, were selected. They were give metformin for one month, 1 gr a day; after one month, they were assessed for BMI, 2hPP and FBS. Due to gastrointestinal complications, 4 patients were excluded from the research. Paired t-test was used in comparing the befor-after response means.
Results: After using metformin, cholesterole and triglyceride dropped by 9.26±2.1 and 54.02±50.51 mg/dl respectively. Also, metformin induced a significant decrease in FBS, 2h postprandial glucose and body weight. No significant relationship was observed between the mean weight loss and factors of age and sex.
Conclusion: In the present study, metformin reduced blood sugar, lipids and body weight.
Keywords
)